These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 27766545)
1. From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer? D'Argento E; Rossi S; Schinzari G; Strippoli A; Basso M; Cassano A; Barone C Curr Treat Options Oncol; 2016 Dec; 17(12):59. PubMed ID: 27766545 [TBL] [Abstract][Full Text] [Related]
2. Novel agents in second-line therapy for EGFR wild-type Advanced Non-Small-Cell Lung Cancer. El Amarti L; Elghissassi I; Layachi M; Mrabti H; Errihani H Gulf J Oncolog; 2016 May; 1(21):84-8. PubMed ID: 27250896 [TBL] [Abstract][Full Text] [Related]
3. New options on the horizon for nononcogene addicted non-small-cell lung cancer. Paglialunga L; Ricciardi S; D'Arcangelo M Future Oncol; 2018 Jun; 14(13s):19-28. PubMed ID: 29989449 [TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Reck M; Garassino MC; Imbimbo M; Shepherd FA; Socinski MA; Shih JY; Tsao A; Lee P; Winfree KB; Sashegyi A; Cheng R; Varea R; Levy B; Garon E Lung Cancer; 2018 Jun; 120():62-69. PubMed ID: 29748017 [TBL] [Abstract][Full Text] [Related]
5. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer. Santana-Davila R; Chow LQ Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785 [No Abstract] [Full Text] [Related]
6. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449 [TBL] [Abstract][Full Text] [Related]
12. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer]. Wang S; Mao Y Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):371-380. PubMed ID: 32283581 [TBL] [Abstract][Full Text] [Related]
13. Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions. Custodio A; de Castro J Crit Rev Oncol Hematol; 2012 Jun; 82(3):338-60. PubMed ID: 21908201 [TBL] [Abstract][Full Text] [Related]
14. The role of combination chemo-immunotherapy in advanced non-small cell lung cancer. Rocco D; Della Gravara L; Battiloro C; Gridelli C Expert Rev Anticancer Ther; 2019 Jul; 19(7):561-568. PubMed ID: 31188040 [No Abstract] [Full Text] [Related]
15. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. Popat S; Mellemgaard A; Fahrbach K; Martin A; Rizzo M; Kaiser R; Griebsch I; Reck M Future Oncol; 2015; 11(3):409-20. PubMed ID: 25478720 [TBL] [Abstract][Full Text] [Related]
16. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Ettinger DS; Wood DE; Aisner DL; Akerley W; Bauman J; Chirieac LR; D'Amico TA; DeCamp MM; Dilling TJ; Dobelbower M; Doebele RC; Govindan R; Gubens MA; Hennon M; Horn L; Komaki R; Lackner RP; Lanuti M; Leal TA; Leisch LJ; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Reckamp K; Riely GJ; Schild SE; Shapiro TA; Stevenson J; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M J Natl Compr Canc Netw; 2017 Apr; 15(4):504-535. PubMed ID: 28404761 [TBL] [Abstract][Full Text] [Related]
17. Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. Genestreti G; Grossi F; Genova C; Burgio MA; Bongiovanni A; Gavelli G; Bartolotti M; Di Battista M; Cavallo G; Brandes AA Future Oncol; 2014 Oct; 10(13):2081-96. PubMed ID: 25396779 [TBL] [Abstract][Full Text] [Related]
18. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231 [TBL] [Abstract][Full Text] [Related]
19. Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients? Morabito A BMC Med; 2018 Feb; 16(1):24. PubMed ID: 29448944 [TBL] [Abstract][Full Text] [Related]
20. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study. Yang YJ; Park JC; Kim HK; Kang JH; Park SY Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]